Most big pharma players have put COVID-19 behind them when it comes to R&D but AstraZeneca PLC's continuing efforts to develop next-generation antibodies for people who do not respond adequately to vaccination are bearing fruit.
The UK major has presented the first in vitro data on AZD3152 at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Denmark, which show that the investigational COVID-19 long-acting antibody neutralizes all known variants of concern identified to date. The drug, licensed from RQ Biotechnology Ltd